In this work, five different dextran-based cryogels for controlled drug release are investigated. Vitamin B12 was used as a model drug for in vitro release tests. Two different drug-loading procedures were adopted, leading to very different drug release curves. Indeed, a fast Fickian release was observed when freeze-dried samples of DEX40PEG360MA and DEX40PEG500MA were infused with the drug after cryogel formation. On the contrary, a slowed highly non-Fickian behavior arises when the drug is loaded before the low-temperature crosslinking step, leading to the cryogel formation. The non-Fickian drug release, observed for all the five different dextran-based cryogels investigated, is actually due to the cryoconcentration phenomenon, modeled with a two-step release process. The proposed transport model accurately predicts experimental release curves characterized by a long lag time, confirming that dextran-based cryogels are suitable for controlled release.
Experimental and Modelling Study of Controlled Release from Dextran-Based Cryogels / Lauriola, Carolina; Di Muzio, Laura; Paolicelli, Patrizia; Casadei, Maria Antonietta; Sergi, Claudia; Tirillò, Jacopo; Carriero, Vito Cosimo; Adrover, Alessandra. - In: PHARMACEUTICS. - ISSN 1999-4923. - 16:10(2024). [10.3390/pharmaceutics16101256]
Experimental and Modelling Study of Controlled Release from Dextran-Based Cryogels
Lauriola, Carolina;Di Muzio, Laura;Paolicelli, Patrizia;Casadei, Maria Antonietta;Sergi, Claudia;Carriero, Vito Cosimo;Adrover, Alessandra
2024
Abstract
In this work, five different dextran-based cryogels for controlled drug release are investigated. Vitamin B12 was used as a model drug for in vitro release tests. Two different drug-loading procedures were adopted, leading to very different drug release curves. Indeed, a fast Fickian release was observed when freeze-dried samples of DEX40PEG360MA and DEX40PEG500MA were infused with the drug after cryogel formation. On the contrary, a slowed highly non-Fickian behavior arises when the drug is loaded before the low-temperature crosslinking step, leading to the cryogel formation. The non-Fickian drug release, observed for all the five different dextran-based cryogels investigated, is actually due to the cryoconcentration phenomenon, modeled with a two-step release process. The proposed transport model accurately predicts experimental release curves characterized by a long lag time, confirming that dextran-based cryogels are suitable for controlled release.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.